Home
overview
The worldwide Diagnostics industry has grown rapidly in the past few years and is now well established. New diagnostic tools are transforming the world of medicine and look set to radically change the way we approach illness. The Diagnostics industry has increased at a phenomenal rate, driven by the demands of physicians and patients for improved healthcare and early diagnosis.

This event will explore the key technology sectors within the worldwide diagnostics industry, examining which market and technology trends are important and what this means for your company.

Important issues to be discussed will include how you can improve your market share, how to select suitable partners for successful mergers and acquisitions and where new market opportunities lie. Moreover you will gain an insight into what the leading companies are looking for and their views on the future of the industry.

The conference will also include a detailed look at market trends within the key technology sectors, including diabetes, coronary heart disease, molecular diagnostics, cancer diagnosis, theranostics and personalised medicine.

You will also learn about the regulatory requirements in the US and EU from industry experts.

A unique opportunity to learn from leading industry experts including:

  • Heino Von Prondzynski, Member, Executive Committee & Head, Diagnostics, F Hoffman-La Roche
  • Dr William Wallen, Senior Vice President, Research, Bayer Diagnostics
  • Edward Michael, Corporate Vice President & General Manager, Abbott
  • Dr Varavani Dwarki, Director, Aventis
  • George Zajicek, Business Development Director, Axis-Shield Diagnostics
  • Anne Bailey, Vice President, Diagnostics, Nuvelo (formally Variagenics)
  • Dr Bernd Haase, Senior Business Development Manager, Europe, Affymetrix
  • Dr Jean-Michel Cosséry, Executive Vice President, Product Strategy, Amersham Health

Benefits of Attending

  • BUSINESS STRATEGIES: explore the opportunities that arise from collaborations, strategic alliances and outsourcing
  • REGULATIONS: find out how recent regulation changes will affect your company
  • POINT OF CARE TESTING: review the current markets and learn how they will grow
  • GLUCOSE MONITORING: gain an insight into how the glucose testing markets will develop
  • HEART DISEASE: discover how the key technologies are performing and where the new opportunities lie
  • MOLECULAR DIAGNOSTICS: learn how this promising industry will shape up
  • CANCER DIAGNOSTICS: examine the current global landscape, discover where future market potential lies
  • PERSONALISED MEDICINE: discover the strategic advantages and points of impact

Conference programme

9:00 Chairperson's Opening Remarks

Doris-Ann Williams

Doris-Ann Williams, Director General, British In Vitro Diagnostics Association (BIVDA)

9:10 KEYNOTE ADDRESS

Andy Anderson

Andy Anderson, Managing Director, Crawford Medical

  • An overview of the current state of the global diagnostics industry
  • Global trends and counter trends
  • Market segments - home diagnostics, point of care, molecular diagnostics and cancer diagnostics
  • Opportunities and threats to the industry
  • Sources of market data
  • Strategic planning in diagnostics
  • 9:40 INDUSTRY CONSOLIDATION

    Dr William Wallen

    Dr William Wallen, Senior Vice President, Research, Bayer Diagnostics

  • Driving factors for consolidation
  • How will it affect the IVD industry?
  • Advantages and disadvantages of the consolidation trend
  • What does it mean for Bayer Diagnostics?
  • Impact on the future of diagnostics
  • 10:20 CASE STUDY : ROCHE

    Heino Von Prondzynski

    Heino Von Prondzynski, Member, Executive Committee & Head, Diagnostics, F Hoffman-La Roche

  • What the big players are looking for
  • How to select suitable partners
  • How a merger will benefit you
  • Potential problems that may occur
  • Why fragmentation still exists
  • 11:00 Morning Coffee

    11:20 CASE STUDY: LIFESCAN

    Dr David Horwitz

    Dr David Horwitz, Vice President, Medical & Clinical Affairs, LifeScan

  • Brief outline of the technology
  • The various roles of glucose monitoring in managing diabetes
  • The growth of the markets
  • The industry prospects
  • Future markets
  • 12:00 OUTSOURCING AS A STRATEGY

    Jeffrey DuBois

    Jeffrey DuBois, Vice President, Business Development, Nova Biomedical
    View Bio

  • Learn how to enhance your product development cycle
  • How will outsourcing enhance your company?
  • Gain an insight into the strategy for outsourcing
  • What are the benefits of outsourcing?
  • Learn about the problems you may encounter and how to avoid them
  • 12:40 Networking Lunch

    14:00 KEY TECHNOLOGY DRIVES

    Edward Michael

    Edward Michael, Corporate Vice President & General Manager, Abbott

  • Key technology sectors
  • The technologies that are big
  • The technologies that are going to be big
  • Predicted growth
  • 14:40 POINT OF CARE TESTING

    Clint Severson

    Clint Severson , Chairman, President & Chief Executive Officer, Abaxis

  • The technologies involved
  • Market analysis: the leading suppliers
  • Cost pressures and perceived barriers
  • Moderators of growth
  • Importance and benefits of in office testing
  • Attitudes of critical care nurses, physicians and doctors
  • 15:20 Afternoon Tea

    15:40 HEART DISEASE DIAGNOSTICS

    George Zajicek

    George Zajicek, Business Development Director, Axis-Shield Diagnostics

  • What are the specific areas of cardiovascular diagnosis?
  • Learn what products are on the market and how they are performing
  • Gain an understanding of the current market size and how it is set to grow
  • What are the hot topics of research and when will they emerge from R&D?
  • Where do future opportunities lie?
  • 16:20 A1C: THE GLUCOSE OF TOMORROW?

    John Curtis

    John Curtis, Managing Director, Diagnostics, Provalis

  • Diabetes disease management - glucose and A1c in partnership
  • The technologies and marketing strategies employed in today’s A1c testing market
  • The A1c Point of Care market inside and outside of the USA
  • The historic parallels between glucose and A1c
  • The future of A1c testing
  • 17:00 Chairperson’s Closing Remarks and Close of Day One
    Followed by SMi's Networking Drinks Reception

    9:00 Chairman's Opening Remarks

    Andy Anderson

    Andy Anderson, Managing Director, Crawford Medical

    9:10 MOLECULAR DIAGNOSTICS

    Anne Bailey

    Anne Bailey, Vice President, Diagnostics, Nuvelo (formally Variagenics)

  • Identification of the current technology trends
  • A global assessment through an exploration of the current landscape
  • Review of the technology platforms including immunoassays, probe-based nucleic acid assays, microarrays and sequencing
  • Identify feasible market opportunities through the identification of expanding markets
  • 9:40 ONCOLOGY AND MOLECULAR DIAGNOSTICS

    Jeffrey Walsh

    Jeffrey Walsh, Vice President, Business Development & Strategy, EXACT Sciences

  • Intellectual property in diagnostics
  • Technology Licensing vs product development
  • Commercialization/ partnering strategies
  • Molecular diagnostics and oncology- the opportunity
  • Outline of EXACT’s technologies and their applications
  • EXACT’s commercial plan
  • 10:20 MICROARRAYS ARE APPROACHING DIAGNOSTIC APPLICATIONS

    Dr Bernd Haase

    Dr Bernd Haase, Senior Business Development Manager, Europe, Affymetrix

  • Review of the microarray industry and its market segmentation
  • The importance of technological developments for high-throughput analysis
  • Breakthrough applications in RNA expression analysis
  • Novel high density microarray assays for genotyping
  • Why are collaborations essential to accelerate growth?
  • Market opportunities for diagnostic microarrays
  • 11:20 THE DIAGNOSTIC IMAGING COMPANY

    Dr Jean-Michel Cosséry

    Dr Jean-Michel Cosséry, Executive Vice President, Product Strategy, Amersham Health

  • What are the positive and negative aspects of aligning diagnostic and therapeutic companies?
  • With targeted medicine will the pharmaceutical industry lose or gain market share?
  • The role in vivo molecular imaging will play in personalised medicine
  • Which technologies will be used - are these in vivo technologies a barrier to entry?
  • In vivo diagnostic imaging - threat or opportunity to the pharmaceutical industry?
  • How diagnostic pharmaceutical and therapeutic pharmaceutical companies can work together for mutual benefit to achieve the personalised medicine goal
  • 12:00 DIAGNOSTICS… AS PART OF THE CURE

    Piere Désy

    Piere Désy, President & Chief Executive Officer, DiagnoCure

  • The rapid emergence of in vitro cancer diagnostics
  • Our technologies and approach to market
  • ImmunoCytTM/uCyt+TM - bladder cancer diagnostics
  • uPM3TM - prostate cancer diagnostics
  • LCM10 - lung cancer diagnostics
  • Business strategy, highlights and objectives
  • 14:00 REGULATIONS: A US PERSPECTIVE

    Thomas Soriano

    Thomas Soriano, President & Chief Executive Officer, Diagnostic Oncology CRO

  • Introduction to the new IVD office
  • Review of the current issues in the US market
  • The new initiatives you should be aware of
  • How new initiatives will affect your company
  • Reimbursement issues
  • 14:40 REIMBURSEMENT PRACTICES IN THE EU

    Paula Wittels

    Paula Wittels, Director, Operations, Quintiles

  • First understand local disease management
  • Identify the payers and budget holders
  • Appreciate the significance of formal listings
  • Understand the role of other guidance
  • Prepare to meet all the requirements
  • Use Health Technology Assessment to your advantage
  • 15:20 FUTURE DEVELOPMENTS

    Sander Tufte

    Sander Tufte, Director, Theranostics, Axis-Shield

  • An outline of the concept
  • Features and benefits of theranostics
  • Market opportunities and growth potential
  • Current strategies
  • 16:00 Chairman's Closing Remarks followed by Afternoon Tea.
    Close of Conference

    +

    Workshops

    Innovation in the Product Development Cycle
    Workshop

    Innovation in the Product Development Cycle

    The Hatton, at etc. venues
    27th June 2003
    London, United Kingdom

    The Hatton, at etc. venues

    51/53 Hatton Garden
    London EC1N 8HN
    United Kingdom

    The Hatton, at etc. venues

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.